摘要
目的：观察进展型ＮＨＬ国际预后指征（ＩＰＩ）对用标准方案治疗的中国进展型非霍奇金氏淋巴瘤预后的预测作用。方法：分析１９９１年－１９９３年间病理组织学和免疫组化确诊的进展型ＮＨＬ１２１例。按ＩＰＩ分组，全组分成低度危险组、低中度危险组、高中度危险组和高度危险组。结果：低危组、低中度危组、高中度组和高危组患者的ＣＲ率分别是９０６％、８０６％、７２７％和４１９％，３年无病生存率（ＤＦＳ）分别是５９１％、４７２％、３１８％和９７％。结论：ＩＰＩ对选择常规化疗疗效差的高危进展型ＮＨＬ病例的指示作用，也适用于中国的进展型ＮＨＬ。
Objective: To
research the international prognostic index(IPI) for predicting outcome in Chinese patients with
aggressive nonHodgkin's lymphoma treatment with standard regimen. Methods: From 1991 to
1993, a total of 121 patients with histologically and immunohistochemistry proven of
aggressive nonHodgkin's lymphoma were analysed.According to IPI, the patients were divided
with low risk, lowintermediate risk, highintermediate risk and high risk groups.THZResults: The
patients in low risk,low intermediate risk, highintermediate risk and high risk group had a
completeresponse rates of 906%, 806%,727%,and 419%,respectively.The threeyear diseasefree
suvival rates of the four groups were 591%,472%,318%and 97%,respectively.Conclusions:The
international prognostic index should be also suitable to predict highrisk Chinese patients with
aggressive nonHodgkin's lymphoma who are not effectively treated with standard regimens.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第3期320-323,共4页
Chinese Journal of Cancer
